Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Men with high-risk, localized prostate cancer who decide on surgery as their first-line treatment of choice are sometimes faced with the question of whether to undergo “immediate” adjuvant radiation therapy after their surgery or to do nothing and wait to see if salvage radiation therapy becomes necessary.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: adjuvant, outcome, prostatectomy, radiation, salvage | Leave a Comment »
A new paper from the Seattle group, already available on line, has offered 15-year follow-up data on the outcomes after treatment with brachytherapy alone in their long series of patients.
Filed under: Management, Treatment | Tagged: 15-year, brachytherapy, localized, outcome | 3 Comments »
Every set of evidence-based best practice guidelines that we are aware of discourage routine imaging studies following diagnosis of localized prostate cancer in low-risk prostate cancer patients. There are exceptional patients for whom such imaging may be appropriate, but they are most certainly the exception and not the routine.
Filed under: Uncategorized | 6 Comments »
Surgical removal of samples of the pelvic lymph nodes at the time of radical prostatectomy (RP) — known as pelvic lymph node dissection (PLND) — is still the most accurate method available to determine the presence or absence of lymph nodes positive for cancer (pN1 disease) in a patient with cancer of the prostate.
Filed under: Management, Treatment | Tagged: pelvic lymph node dissection, PNLD, risk, stage | Leave a Comment »
ACR 03-12 is a Phase II clinical trial designed by the American College of Radiology to test the safety and efficacy of 82 GyE (Gray equivalent) delivered using conformal proton beam radiation therapy (PBRT) for the treatment of localized prostate cancer.
Filed under: Management, Treatment | Tagged: high-dose, PBRT, proton beam radiation therapy, toxicity | 2 Comments »
According to a media release from the University of Pennsylvania Health System, (and another from the American Society of Radiation Oncology [ASTRO]), intensity-modulated radiation therapy (IMRT) is associated with fewer complications than traditional, three-dimensional conformal radiation therapy (3D-CRT) in the treatment of non-metastatic prostate cancer.
Filed under: Management, Living with Prostate Cancer | Tagged: radiation, outcome, IMRT, side effects, intensity-modulated, 3D-CRT, conformal | Leave a Comment »
The prostate cancer antigen 3 or PCA3 test is already widely used to further assess risk for prostate cancer in a man with a high PSA result (potentially indicative of risk for prostate cancer) but an initial negative biopsy. The “cut point” for re-biopsy is considered to be a PCA3 score of ≥ 35.
Filed under: Diagnosis, Risk | Tagged: biopsy, PCA3, re-biopsy, risk | 6 Comments »
Soy isoflavones are known to have antioxidant and anti-inflammatory activities and to sensitize prostate cancer cells to radiation therapy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adverse effects, complications, isoflavone, radiation therapy, soy | 1 Comment »
A presentation to be given next week at the upcoming annual meeting of the American Society for Radiation Oncology (ASTRO) will suggest that men initially diagnosed with localized prostate cancer and who take an anti-clotting agent are at significantly lower risk for prostate cancer-specific death at 10 years of follow-up.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: anti-clotting agent, aspirin, prostate cancer-specific mortality, risk | 2 Comments »
The ability to monitor and predict outcomes of patients in treatment for metastatic castration-resistant prostate cancer (mCRPC) is becoming increasingly important as better treatments for such patients start to become available or enter clinical trials.
Filed under: Management, Treatment | Tagged: alkaline phosphatase, chemotherapy, mCRPC, outcome, PSA, survival | Leave a Comment »
As we reported at the time, at the annual meeting of the American Society for Clinical Oncology, in June this year, Warde et al. presented the initial survival data from a large, multi-center trial of androgen deprivation therapy (ADT) + radiation compared to ADT alone for patients with high-risk, localized prostate cancer.
Filed under: Management, Treatment | Tagged: "high risk", ADT, androgen deprivation therapy, localized, radiation | Leave a Comment »
According to a story on today’s Wall Street Journal Health Blog, the U.S. Preventive Services Task Force (USPSTF) has canceled a meeting originally scheduled for November 1-2, when it was expected to re-vote on recommendations regarding the use of prostate cancer screening.
Filed under: Uncategorized | Tagged: recommendation, risk, screening, USPSTF | 2 Comments »
On December 1 this year the US Food & Drug Administration’s Oncologic Drug Advisory Committee (ODAC) will meet to hear arguments in favor of — and probably some against — the approval of dutasteride (Avodart) for “the reduction in the risk of prostate cancer in men at increased risk of developing the disease.”
Filed under: Diagnosis, Drugs in development, Management, Prevention, Risk, Uncategorized | Tagged: dutasteride, Prevention, reduction, risk | Leave a Comment »
An Australian company called Broadvector is initiating a Phase I clinical trial of a new two-stage, gene-based therapy for the treatment of prostate cancer.
Filed under: Drugs in development, Management | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site